A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 6106 participants.
Also called NCT07876492
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 6,106 participants
- Sponsor
- Registry
-
NCT07876492 -
2026-527406-20-00
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07876492. Randomized; quadruple masking; primary purpose prevention. Start 2026-11-20 (anticipated); primary completion 2029-12-15 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants
- Acronym
- ROXI-DAISEN
- Condition
- Secondary Stroke
- Intervention (Drug)
- Cenvacibart
- Intervention (Drug)
- Placebo
- Lead sponsor
- Regeneron Pharmaceuticals
Record details
- Record id
cardio:ct-nct07876492- Content hash
c60b77dcee6b79c0471dee07caf415317e4de16dc9f1cb01409e248aea370913